Volker Heinemann, University of Munich, Munich, Germany
У вашего броузера проблема в совместимости с HTML5
2013 ASCO Annual Meeting Pressconference, Saturday's Highlighted Research of the Day, June 1 http://www.oncoletter.ch Volker Heinemann, University of Munich, Munich, Germany: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).